T-lymphocyte receptors and co-stimulatory molecules

T-lymphocyte receptors and co-stimulatory molecules are a broad class of cell surface proteins that regulate the activation, differentiation, and effector functions of T-cells (StatPearls, 2023). The T-cell receptor (TCR) complex provides the primary signal for antigen recognition, while co-stimulatory molecules like CD28 and OX40 provide essential secondary signals for robust immune responses (Janeway's Immunobiology). Conversely, co-inhibitory molecules such as PD-1 and CTLA-4 act as 'checkpoints' to maintain self-tolerance and prevent excessive tissue damage (Nature Reviews Cancer, 2018). In oncology, monoclonal antibodies targeting these inhibitory receptors (e.g., pembrolizumab, ipilimumab) have become standard of care by 'releasing the brakes' on the immune system to attack cancer cells (NIH, National Cancer Institute). In contrast, fusion proteins like abatacept target co-stimulatory pathways to treat autoimmune diseases such as rheumatoid arthritis by dampening T-cell activity (PubMed, PMID: 29461460). The therapeutic manipulation of these pathways is a central strategy in modern immunotherapy, though it carries risks of immune-related adverse events due to the loss of self-tolerance.

Other names

T-cell receptors and costimulatory moleculesT-cell activation receptorsTCR and co-signaling moleculesT-lymphocyte activation complex

Modulation of T-lymphocyte activation and effector function by either blocking inhibitory checkpoint signals to enhance anti-tumor immunity or by inhibiting stimulatory signals to suppress aberrant immune responses (Nature Reviews Drug Discovery, 2018).